Sarepta Therapeutics Inc (SRPT)

Quick ratio

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Cash	US$ in thousands	427,300	428,430	541,932	851,929	871,668	966,777	1,038,620	868,565	1,233,880	2,115,870	1,599,110	1,697,280	1,481,840	1,502,650	1,474,640	1,639,960	1,764,210	835,080	724,829	808,591
Short-term investments	US$ in thousands	963,500	1,247,820	1,191,610	1,008,790	1,010,430	1,022,600	1,033,900	1,059,450	779,548	0	0	30,000	255,997	435,923	341,467	421,349	406,940	289,668	324,063	294,478
Receivables	US$ in thousands	378,806	403,058	318,855	236,808	223,836	217,939	201,509	203,854	178,194	152,990	149,787	127,520	118,203	101,340	121,827	104,028	106,875	90,879	68,032	56,981
Total current liabilities	US$ in thousands	608,709	653,659	450,743	498,654	536,884	619,604	602,916	545,566	454,962	452,733	373,443	425,022	364,736	416,026	378,388	354,896	306,429	264,767	215,856	162,089
Quick ratio		2.91	3.18	4.55	4.21	3.92	3.56	3.77	3.91	4.82	5.01	4.68	4.36	5.09	4.90	5.12	6.10	7.43	4.59	5.17	7.16

March 31, 2024 calculation

Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($427,300K + $963,500K + $378,806K) ÷ $608,709K
= 2.91

The quick ratio of Sarepta Therapeutics Inc has shown a fluctuating trend over the past few quarters. The quick ratio measures the company's ability to meet its short-term obligations using its most liquid assets.

The quick ratio has generally been above 1, indicating that the company has enough liquid assets to cover its current liabilities. A quick ratio above 1 is considered healthy as it suggests a company is able to pay off its short-term obligations without relying heavily on inventory sales.

Looking at the trend, the quick ratio has been above 3 in most quarters, indicating a strong liquidity position. The highest quick ratio was observed in March 2020 at 7.43, signaling a robust ability to cover short-term liabilities with liquid assets.

However, the quick ratio has shown some fluctuations over the quarters, which could be due to changes in the company's current assets and liabilities composition. Investors and analysts typically prefer a stable and consistent quick ratio over time, although variations can be expected depending on the company's business cycle and operating environment.

Overall, Sarepta Therapeutics Inc's quick ratio indicates a healthy liquidity position, which is important for ensuring the company's short-term financial stability.